{"article_title": "Senate Aging Committee Could Hold Outgoing Valeant CEO in Contempt", "article_keywords": ["aging", "outgoing", "pearson", "statement", "senate", "valeant", "hearing", "ceo", "deposition", "investigation", "committee", "mr", "hold", "company", "contempt"], "article_url": "https://morningconsult.com/alert/senate-aging-committee-hold-outgoing-valeant-ceo-contempt/", "article_text": "The Senate Special Committee on Aging scheduled a meeting to begin contempt proceedings against Michael Pearson, the outgoing CEO of Valeant Pharmaceuticals, a company under investigation by the committee.\n\nPearson, who is remaining in his position until the company names his successor, did not comply with a subpoena to attend a deposition Monday related to the committee\u2019s investigation into drug prices, said Sens. Susan Collins (R-Maine) and Claire McCaskill (D-Mo.), the respective chairwoman and ranking member of the committee.\n\n\u201cHis actions and those of Valeant are central to the investigation pursued by this Committee,\u201d they said in a joint statement. \u201cTherefore, it is our intent to initiate contempt proceedings against Mr. Pearson.\u201d\n\nThe committee launched an investigation into prescription drug prices last year. Last month it held a hearing focused on Turing Pharmaceuticals, and subpoenaed a former official and current employees, including Interim CEO Ron Tilles, to testify about the company\u2019s business practices.\n\nPearson was subpoenaed to appear before the committee for a hearing on April 27.\n\nValeant released a statement Monday saying the company had asked Pearson to comply with the subpoena.\n\n\u201cThe Board has requested Mr. Pearson\u2019s cooperation in connection with a subpoena for deposition from the Senate Committee on Aging prior to the Committee\u2019s scheduled April 27 hearing,\u201d the statement said. \u201cThe Board understands that Mr. Pearson is in dialogue with the Senate Committee on Aging regarding his deposition and that those discussions are ongoing.\u201d", "article_metadata": {"msapplication-config": "/icons/browserconfig.xml", "viewport": "width=device-width, initial-scale=1", "og": {"site_name": "Morning Consult", "description": "The Senate Special Committee on Aging scheduled a meeting to begin contempt proceedings against Michael Pearson, the outgoing CEO of Valeant Pharmaceuticals, a company under investigation by the committee. Pearson, who is remaining\u00a0in his position until the company names his successor, did not comply with a subpoena to attend a deposition Monday related to the... read more", "title": "Senate Aging Committee Could Hold Outgoing Valeant CEO in Contempt - Morning Consult", "locale": "en_US", "image": "https://morningconsult.com/wp-content/themes/morning-consult/img/MC_logo_twitter_fb.png", "url": "https://morningconsult.com/alert/senate-aging-committee-hold-outgoing-valeant-ceo-contempt/", "type": "article"}, "twitter": {"description": "The Senate Special Committee on Aging scheduled a meeting to begin contempt proceedings against Michael Pearson, the outgoing CEO of Valeant Pharmaceuticals, a company under investigation by the committee. Pearson, who is remaining\u00a0in his position until the company names his successor, did not comply with a subpoena to attend a deposition Monday related to the... read more", "creator": "@melmcintire", "image": "https://morningconsult.com/wp-content/themes/morning-consult/img/MC_logo_twitter_fb.png", "title": "Senate Aging Committee Could Hold Outgoing Valeant CEO in Contempt - Morning Consult", "site": "@morningconsult", "card": "summary"}, "msapplication-TileColor": "#2b5797", "msapplication-TileImage": "/icons/mstile-144x144.png", "article": {"publisher": "https://www.facebook.com/Morning-Consult-183517831660100/", "section": "Congress"}, "theme-color": "#ffffff"}, "article_summary": "The Senate Special Committee on Aging scheduled a meeting to begin contempt proceedings against Michael Pearson, the outgoing CEO of Valeant Pharmaceuticals, a company under investigation by the committee.\n\u201cThe Board understands that Mr. Pearson is in dialogue with the Senate Committee on Aging regarding his deposition and that those discussions are ongoing.\u201d\n\u201cTherefore, it is our intent to initiate contempt proceedings against Mr. Pearson.\u201dThe committee launched an investigation into prescription drug prices last year.\n\u201cThe Board has requested Mr. Pearson\u2019s cooperation in connection with a subpoena for deposition from the Senate Committee on Aging prior to the Committee\u2019s scheduled April 27 hearing,\u201d the statement said.\n\u201cHis actions and those of Valeant are central to the investigation pursued by this Committee,\u201d they said in a joint statement."}